Disease Severity, Interleukin-6, Plaque Psoriasis
Conditions
Brief summary
This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.
Detailed description
Psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population. Interleukin (IL)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. It is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. Increased IL-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis
Interventions
OTHEREnzyme-linked immunosorbent assay (ELISA)
The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
Sponsors
Tanta University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age above 18 years. * Both sexes. * Patients clinically diagnosed with plaque psoriasis.
Exclusion criteria
* Patients who had received any treatment for psoriasis in the last three months. * Patients with other types of psoriasis. * Those currently receiving systemic treatment. * Individuals with other inflammatory diseases. * Pregnant or lactating women. * Those using contraceptive pills. * Patients with metabolic conditions like diabetes mellitus or thyroid disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease severity | 3 months post-procedure | Disease severity was assessed using the Psoriasis Area and Severity Index (PASI), categorizing patients into mild (PASI \<5), moderate (PASI 5-10), and severe (PASI \>10) groups. |
Countries
Egypt
Outcome results
None listed